The cost-effectiveness analysis of combination of peginterferon alfa-2a and ribavirin versus combination of peginterferon alfa-2b and ribavirin in chronic hepatitis C in Poland

被引：0
|
作者：
Orlewska, E [1 ]
机构：
[1] Ctr Pharmacoeconom, Warsaw, Poland
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62487-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：356 / 356
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness analysis of peginterferon alfa-2a and ribavirin versus interferon alfa-2b and ribavirin in chronic hepatitis C in Poland
    Orlewska, E
    Juszczyk, J
    VALUE IN HEALTH, 2003, 6 (06) : 749 - 750
  • [2] Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Hepatitis C
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18): : 1808 - 1809
  • [3] Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C
    Yeh, Frank
    Gordon, Fredric D.
    FUTURE VIROLOGY, 2007, 2 (06) : 553 - 563
  • [4] Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
    Bernfort, Lars
    Sennfalt, Karin
    Reichard, Olle
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (6-7) : 497 - 505
  • [5] Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Hepatitis C REPLY
    Albrecht, Janice
    McHutchison, John
    Sulkowski, Mark
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18): : 1809 - 1809
  • [6] Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
    Brixner, Diana I.
    Ye, Xin
    Chu, Teng-Chiao
    Blumentals, William A.
    Hassanein, Tarek I.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (24) : 2171 - 2178
  • [7] Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin
    Rustgi, V. K.
    Esposito, S.
    Hamzeh, F. M.
    Shiffman, M. L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (05) : 433 - 440
  • [8] Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain
    Turnes, Juan
    Romero-Gomez, Manuel
    Planas, Ramon
    Sola, Ricard
    Garcia-Samaniego, Javier
    Diago, Moises
    Crespo, Javier
    Calleja, Jose Luis
    Rubio-Terres, Carlos
    Ventayol, Pere
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (09): : 555 - 564
  • [9] Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    McHutchison, John G.
    Lawitz, Eric J.
    Shiffman, Mitchell L.
    Muir, Andrew J.
    Galler, Greg W.
    McCone, Jonathan
    Nyberg, Lisa M.
    Lee, William M.
    Ghalib, Reem H.
    Schiff, Eugene R.
    Galati, Joseph S.
    Bacon, Bruce R.
    Davis, Mitchell N.
    Mukhopadhyay, Pabak
    Koury, Kenneth
    Noviello, Stephanie
    Pedicone, Lisa D.
    Brass, Clifford A.
    Albrecht, Janice K.
    Sulkowski, Mark S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (06): : 580 - 593
  • [10] Peginterferon Alfa 2a/ribavirin versus Peginterferon Alfa 2b/ribavirin combination therapy in chronic Hepatitis C genotype 3
    Khan, Arif Q.
    Awan, Ali
    Shahbuddin, Sultan
    Igbal, Qamar
    GASTROENTEROLOGY, 2007, 132 (04) : A200 - A200
12345